Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in Northern and Southern Sweden (original) (raw)

Abstract

Objective: To examine the possible relationships of breast cancer risk to prediagnostic plasma levels of insulin; insulin-like growth factor-I (IGF-I); and IGF-binding proteins -1, -2, and -3. Methods: Within two prospective cohorts in Umeå and Malmö we measured plasma concentrations of insulin, IGF-I, and IGFBPs for a total of 513 incident breast cancer cases and 987 matched controls. Results: Globally, risk was unassociated with levels of IGF-I, IGFBP-3, or IGF-I adjusted for IGFBP-3. When breaking down the analysis by subgroups of age at blood donation, an increase in risk was observed for increasing levels of IGF-I in women aged 55 or older, in the Umeå cohort only (odds ratios of 1.00, 1.73, 1.76, 1.90; p trend = 0.05). This effect weakened, however, when the analysis was restricted to subjects who did not use exogenous hormones for the treatment of menopausal symptoms. Levels of IGF-I and IGFBP-3 were not related to risk in younger women, recruited before age 50, contrary to observations from previous studies. In a subcohort where blood samples had been collected after at least four hours of fasting, breast cancer risk showed no clear associations with levels of insulin, IGFBP-1, or IGFBP-2. Conclusions: Our results do not confirm earlier findings of an association of plasma IGF-I levels with breast cancer risk especially in young women, but suggest a possible association with postmenopausal breast cancer risk, possibly among ERT/HRT users only. Our results do not support the hypothesis that elevated plasma insulin levels, and reduced levels of IGFBP-1 and IGFBP-2, are associated with increased breast cancer risk.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Thissen JP, Ketelslegers JM, Underwood LE (1994) Nutritional regulation of the insulin-like growth factors. Endocrinol Rev 15: 18-101.
    Google Scholar
  2. Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocrinol Rev 16: 3-34.
    Google Scholar
  3. Rosfjord EC, Dickson RB (1999) Growth factors, apoptosis, and survival of mammary epithelial cells. J Mammary Gland Biol Neoplasia 4: 229-237.
    Google Scholar
  4. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocrinol Rev 21: 215-244.
    Google Scholar
  5. Ng ST, Zhou J, Adesanya OO, Wang J, LeRoith D, Bondy CA (1997) Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nat Med 3: 1141-1144.
    Google Scholar
  6. Hadsell DL, Bonnette SG (2000) IGF and insulin action in the mammary gland: lessons from transgenic and knockout models. J Mammary Gland Biol Neoplasia 5: 19-30.
    Google Scholar
  7. Wennbo H, Tornell J (2000) The role of prolactin and growth hormone in breast cancer. Oncogene 19: 1072-1076.
    Google Scholar
  8. Kaaks R, Lukanova A (2001) Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 60 (In press).
  9. Kaaks R (1996) Nutrition, hormones, and breast cancer: is insulin the missing link? Cancer Causes Control 7: 605-625.
    Google Scholar
  10. Hankinson SE, Willett WC, Colditz GA, et al. (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351: 1393-1396.
    Google Scholar
  11. Toniolo P, Bruning PF, Akhmedkhanov A, et al. (1993) Serum insulin-like growth factor-I and breast cancer. Int J Cancer 88: 828-832.
    Google Scholar
  12. Peyrat JP, Bonneterre J, Hecquet B, et al. (1993) Plasma insulinlike growth factor-I (IGF-I) concentrations in human breast cancer. Eur J Cancer 29A: 492-497.
    Google Scholar
  13. Bruning PF, Van Doorn J, Bonfrer JM, et al. (1995) Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. Int J Cancer 62: 266-270.
    Google Scholar
  14. Bohlke K, Cramer DW, Trichopoulos D, Mantzoros CS (1998) Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology 9: 570-573.
    Google Scholar
  15. Del Giudice ME, Fantus IG, Ezzat S, McKeown-Eyssen G, Page D, Goodwin PJ (1998) Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat 47: 111-120.
    Google Scholar
  16. Petridou E, Papadiamantis Y, Markopoulos C, Spanos E, Dessypris N, Trichopoulos D (2000) Leptin and insulin growth factor I in relation to breast cancer (Greece). Cancer Causes Control 11: 383-338.
    Google Scholar
  17. Clemmons DR (1997) Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev 8: 45-62. IGF-I, IGFBPs, and breast cancer 315
    Google Scholar
  18. Berglund G, Elmstahl S, Janzon L, Larsson SA (1993) The Malmo Diet and Cancer Study. Design and feasibility. J Intern Med 233: 45-51.
    Google Scholar
  19. Campagnoli C, Biglia N, Cantamessa C, Di Sario MM, Lesca L (1997) Effect of progestins on IGF-I serum level in estrogen-treated postmenopausal women. Zentralbl Gynakol 119 (Suppl. 2): 7-11.
    Google Scholar
  20. Ho KK, O'Sullivan AJ, Weissberger AJ, Kelly JJ (1996) Sex steroid regulation of growth hormone secretion and action. Horm Res 45: 67-73.
    Google Scholar
  21. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I (1999) Breast-cancer risk following long-term oestrogenand oestrogen-progestin-replacement therapy. Int J Cancer 81: 339-344.
    Google Scholar
  22. Olsson H, Bladstrom A, Ingvar C, Moller TR (2001) A population-based cohort study of HRT use and breast cancer in southern Sweden. Br J Cancer 85: 674-677.
    Google Scholar
  23. Hammar M, Brynhildsen J, Dabrosin L, et al. (1996) Hormone replacement therapy and previous use of oral contraceptives among Swedish women. Maturitas 25: 193-199.
    Google Scholar
  24. Campagnoli C, Biglia N, Peris C, Sismondi P (1995) Potential impact on breast cancer risk of circulating insulin-like growth factor I modifications induced by oral HRT in menopause. Gynecol Endocrinol 9: 67-74.
    Google Scholar
  25. Bruning PF, Bonfrer JM, Van Noord PA, Hart AA, Jong-Bakker M, Nooijen WJ (1992) Insulin resistance and breast-cancer risk. Int J Cancer 52: 511-516.
    Google Scholar

Download references

Author information

Authors and Affiliations

  1. Unit of Nutrition and Cancer, International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372, Lyon Cedex 08, France
    Rudolf Kaaks, Sabina Rinaldi, Carine Biessy & Elio Riboli
  2. University of Umeå, Sweden
    Eva Lundin, Stefan Söderberg, Per Lenner & Göran Hallmans
  3. Lund University, UMAS, 205 02, Malmö, Sweden
    Jonas Manjer, Lars Janzon & Göran Berglund

Authors

  1. Rudolf Kaaks
  2. Eva Lundin
  3. Jonas Manjer
  4. Sabina Rinaldi
  5. Carine Biessy
  6. Stefan Söderberg
  7. Per Lenner
  8. Lars Janzon
  9. Elio Riboli
  10. Göran Berglund
  11. Göran Hallmans

Rights and permissions

About this article

Cite this article

Kaaks, R., Lundin, E., Manjer, J. et al. Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in Northern and Southern Sweden.Cancer Causes Control 13, 307–316 (2002). https://doi.org/10.1023/A:1015270324325

Download citation